Cover Image
市場調查報告書

MediPoint:冠狀動脈支架 - 全球市場的分析與預測

MediPoint: Coronary Stents - Global Analysis and Market Forecasts

出版商 GlobalData 商品編碼 319555
出版日期 內容資訊 英文 436 Pages
訂單完成後即時交付
價格
Back to Top
MediPoint:冠狀動脈支架 - 全球市場的分析與預測 MediPoint: Coronary Stents - Global Analysis and Market Forecasts
出版日期: 2014年11月17日 內容資訊: 英文 436 Pages
簡介

全球冠狀動脈支架市場,非常多的企業開發創新的技術,是動態且飽和狀態的兩位數市場。隨著微創技術的發展,以及介入心臟病學領域中的迅速進步,應用治療的可能性大幅度擴大了。

本報告提供全球冠狀動脈支架市場相關調查分析、產業概要、未滿足需求、市場機會、推動市場要素、競爭評估、開發中產品驗證、主要企業簡介等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 產業概要

  • 疾病概要
  • 臨床結果
  • 治療趨勢
  • 進入市場
  • 法規問題/回收
  • M&A/主要的聯盟
  • 經濟影響
  • 治療成本

第4章 未滿足需求

  • 特異性病變的良好臨床結果的必要性
  • 排除球囊血管成形術的失敗機制
  • 支架置入後的遲發性心肌梗塞
  • 排除永久性聚合物
  • 支架內血管再阻塞
  • 支架內支架次序
  • 持續性雙重抗血小板療法
  • 缺乏均質的藥物分佈
  • 支架的內皮層化延遲
  • 陰性血管重塑
  • 特定患者族群的有效治療的必要性
  • 對冠狀動脈繞道手術併發症的應對

第5章 市場機會分析

  • 支架設計/平台的改善
  • 混合支架系統
  • 對難治的冠狀動脈適應症的有效治療方法
  • 難治的目標患者族群
  • 新興市場

第6章 推動市場要素、障礙、替代

  • 推動市場要素
  • 市場障礙
  • 市場替代

第7章 競爭評估

  • 概要
  • 冠狀動脈支架技術的發展趨勢
  • 全球企業的市場佔有率
  • 地區企業的市場佔有率

第8章 開發中產品

  • 概要
  • 開發平台:各開發階段
  • 開發中產品簡介

第9章 臨床試驗分析

  • 概要
  • 值得注意的臨床試驗

第10章 現在/未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Abbott Vascular
    • Boston Scientific Corporation
    • Medtronic
    • Alvimedica
    • Amaranth Medical
    • amg International
    • Arterial Remodeling Technologies
    • B. Braun
    • Balton
    • Biosensors International
    • Biotronik
    • Blue Medical
    • Cardionovum
    • C.R. Bard
    • Elixir Medical Corporation
    • eucatech AG
    • Hexacath
    • IRAMED
    • JW Medical Systems
    • 京都醫療設計
    • Lepu Medical Technology
    • MicroPort Scientific Corporation
    • Minvasys
    • MIV Therapeutics
    • Opto Circuits
    • OrbusNeich Medical
    • Relisys Medical Devices
    • REVA Medical
    • Sahajanand Medical Technologies
    • TENTYS
    • Terumo Corporation
    • Translumina
    • Vascular Concepts
    • 其他的企業

第11章 市場預測

  • 市場部門別
  • 各適應症
  • 各地區

第12章 附錄

圖表

目錄
Product Code: GDME0206MAR

The global coronary stents market is a dynamic, double-digit market that is saturated with numerous players developing innovative technologies. Rapid advances in the field of interventional cardiology along with the development of minimally invasive techniques have greatly expanded the potential of therapeutic applications. Coronary stents including bare metal, drug-eluting, covered and bioabsorbable stents can be used to treat coronary artery disease, and optimize outcomes.

Among the different types of stents, drug-eluting stents (DES) dominate the market and are considered to be the gold standard of treatment for coronary artery disease. The rising prevalence of disease and associated risk factors, especially in the emerging markets, and improved outcomes with stenting are expected to drive the adoption of coronary stents in the future. Emerging technologies such as the new generation of DES and bioabsorbable stents (BAS) represent the future of the coronary stent market. BAS offer several benefits, including no metal left behind, enhanced vessel healing, feasibility of future interventions and potentially reducing the need for prolonged dual antiplatelet therapy. With improvements in the design of BAS, they have the potential to become the standard of treatment for coronary artery disease in the future.

This report focuses on the global coronary stents market in the 10 major markets (10MM) (US, France, Germany, Italy, Spain, UK, Japan, China, India, and Brazil) for treating coronary artery disease. The global bare metal stents (BMS) and DES market is determined for the 10 countries covered in this report and provides insight into the competitive landscape, the marketed and pipeline products, the current and emerging players and market analysis of the different stent segments within the market. The report identifies the unmet needs in the market while providing an understanding of physicians' perceptions and decision-making processes in using and evaluating the adoption of different types of coronary stents.

Highlights

Key Questions Answered

  • What is the current and future coronary stents market outlook in the developed and emerging markets What trends are affecting the global coronary stents market
  • Which are the key, high growth markets that stent manufacturers should expand into What coronary stent segments are growing the fastest, and what are the top-selling stents in the category
  • Bare metal and drug-eluting stents have been on the market for many years; however, unmet needs still exist with respect to late and very late thrombosis and the need for prolonged dual anti-platelet therapy. How will emerging technologies such as DES with biodegradable polymer/polymer-free systems and BAS fulfill these unmet needs
  • What clinical factors and technical specifications influence a physician to use one type of coronary stent over another What is physician perception and market outlook of BAS
  • What are the challenges and complications of BAS that have hindered widespread adoption

With developing the next-generation of coronary stents, what aspects of the stent technology are device manufacturers focused on optimizing How will new entrants impact the coronary stents market

Scope

  • An overview of percutaneous coronary interventions, which includes clinical outcomes, diagnosis, and treatment using minimally invasive techniques.
  • Annualized total coronary stents market revenue from 2011-2020 including adoption patterns.
  • Key topics covered include strategic competitor assessment, market characterization, identification of unmet needs, reimbursement considerations, and implications for the coronary stents market.
  • Pipeline analysis: comprehensive list of products across different stages of development that would impact the coronary stents market with emerging trends and designs in development.
  • Analysis of the current and future market competition in the global coronary stents market. Insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • "What Physicians Think" quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. In this report you will understand the perceptions of leading Interventional Cardiologists from around the world. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Industry Overview

  • 3.1. Disease Overview
  • 3.2. Clinical Outcomes
    • 3.2.1. Treatment Guidelines
    • 3.2.2. Treatment Modalities
  • 3.3. Procedure Trends
    • 3.3.1. United States
    • 3.3.2. European Union
    • 3.3.3. Asia-Pacific
    • 3.3.4. Brazil
  • 3.4. Market Access
    • 3.4.1. Regulatory Process
    • 3.4.2. Physician Decision-Making Process
    • 3.4.3. Role of Group Purchasing Organizations
    • 3.4.4. Lack of Clinical Data
    • 3.4.5. Regional-Level Control
    • 3.4.6. Cost Considerations
    • 3.4.7. Reimbursement Trends
  • 3.5. Regulatory Issues/Recalls
    • 3.5.1. Regulatory Issues
    • 3.5.2. Product Recalls
  • 3.6. Mergers and Acquisitions/ Key Partnerships
    • 3.6.1. Medtronic and Covidien
    • 3.6.2. Arterial Remodeling Technologies and Terumo Corporation
    • 3.6.3. MicroPort Scientific Corporation and Cordis Corporation
    • 3.6.4. Alvimedica and CID
    • 3.6.5. ITGI Medical and Vascular Solutions
    • 3.6.6. Terumo Corporation and Onset Medical Corporation
    • 3.6.7. Atrium Medical and Getinge Group
    • 3.6.8. C.R. Bard and ClearStream Technologies
    • 3.6.9. Biosensors International and Devax, CardioMind, and JW Medical Systems
    • 3.6.10. CeloNova Biosciences and Nexeon MedSystems
    • 3.6.11. Medtronic and Invatec
    • 3.6.12. Micell Technologies and Maxcor Lifescience
    • 3.6.13. Boston Scientific Corporation and Guidant Corporation
    • 3.6.14. Abbott Vascular and Guidant Corporation
    • 3.6.15. Kaneka Corporation and Fujisawa Pharmaceuticals
  • 3.7. Economic Impact of Coronary Artery Disease
    • 3.7.1. United States
    • 3.7.2. European Union
    • 3.7.3. Asia-Pacific
    • 3.7.4. Brazil
  • 3.8. Treatment Costs for Coronary Artery Disease

4. Unmet Needs

  • 4.1. Need for Better Clinical Outcomes in Specific Lesions
    • 4.1.1. Chronic Total Occlusions
    • 4.1.2. Small-Vessel Coronary Lesions
    • 4.1.3. Heavily-Calcified and Uncrossable/Undilatable Lesions
    • 4.1.4. Bifurcation Lesions
    • 4.1.5. Saphenous Vein Graft Intervention
  • 4.2. Eliminating Mechanisms of Failure With Balloon Angioplasty
  • 4.3. Late Myocardial Infarction After Stenting
  • 4.4. Eliminating the Permanent Polymer
  • 4.5. In-Stent Restenosis
  • 4.6. Stent-In-Stent Procedures
  • 4.7. Prolonged Dual Antiplatelet Therapy
  • 4.8. Lack of Homogenous Drug Distribution
  • 4.9. Delayed Stent Endothelialization
  • 4.10. Negative Vessel Remodeling
  • 4.11. Need for Effective Therapy for Specific Patient Populations
  • 4.12. Addressing the Complications of Coronary Artery Bypass Grafting

5. Market Opportunity Analysis

  • 5.1. Improve Stent Design/Platform
    • 5.1.1. Stent Coating Technology
    • 5.1.2. Bioabsorbable Stent Technology
    • 5.1.3. Antiproliferative Drug and Elution Kinetics
  • 5.2. Hybrid Stent Systems
  • 5.3. Effective Therapies for Challenging Coronary Indications
    • 5.3.1. Chronic Total Occlusions
    • 5.3.2. Small-Vessel Disease
    • 5.3.3. Bifurcation Lesions
    • 5.3.4. Diffuse Atherosclerotic Disease
    • 5.3.5. Saphenous Vein Graft Intervention
    • 5.3.6. Acute Myocardial Infarction
  • 5.4. Target Challenging Patient Populations
  • 5.5. Emerging Markets

6. Market Drivers, Barriers, and Substitutes

  • 6.1. Market Drivers
    • 6.1.1. Rising Prevalence of Disease
    • 6.1.2. Viable Treatment for Challenging Coronary Indications
    • 6.1.3. Innovations in Stent Technology
    • 6.1.4. Development of Bioabsorbable Stents
    • 6.1.5. Reduce the Need for Prolonged Dual Antiplatelet Therapy
    • 6.1.6. Potential Cost Savings
    • 6.1.7. Use of Imaging Modalities for Accurate Stent Placement
    • 6.1.8. Adoption of Stents in the Emerging Markets
    • 6.1.9. Launch of Bioabsorbable Stents in US and Japan
  • 6.2. Market Barriers
    • 6.2.1. Concerns Regarding Overstenting
    • 6.2.2. Post-ProceduraI Complications of Drug-Eluting Stenting
    • 6.2.3. Risk of Perioperative Adverse Cardiac Events Post-Stenting
    • 6.2.4. Slow Adoption of Bioabsorbable Stents
    • 6.2.5. Lack of Reimbursement
    • 6.2.6. Healthcare Cost-Cutting and Reimbursement
    • 6.2.7. Availability of Venture Capital
    • 6.2.8. Medical Device Excise Tax
  • 6.3. Market Substitutes
    • 6.3.1. Drug-Eluting Balloons
    • 6.3.2. Liquid Drug Delivery Catheter

7. Competitive Assessment

  • 7.1. Overview
  • 7.2. Trends in Coronary Stent Technology Development
    • 7.2.1. Development of Bare Metal Stents
    • 7.2.2. Development of Drug-Eluting Stents
    • 7.2.3. Development of Bioabsorbable Stents
    • 7.2.4. Development of Covered Stents

7.2.5. Coronary Stent Technology SWOT Analysis

  • 7.3. Global Company Market Share
    • 7.3.1. Bare Metal Stent Market Share
    • 7.3.2. Drug-Eluting Stent Market Share
  • 7.4. Regional Company Market Share
    • 7.4.1. US Market Share
    • 7.4.2. EU Market Share
    • 7.4.3. APAC Market Share
    • 7.4.4. Brazil Market Share

8. Pipeline Products

  • 8.1. Overview
  • 8.2. Pipeline by Stage of Development
  • 8.3. Pipeline Product Profiles
    • 8.3.1. Bioabsorbable Stents
    • 8.3.2. Other Types of Vascular Stents

9. Clinical Trial Analysis

  • 9.1. Overview
  • 9.2. Clinical Trials to Watch
    • 9.2.1. Evaluating the Latest and New Generation of Drug-Eluting Stents
    • 9.2.2. Bioabsorbable Stent Clinical Trials
    • 9.2.3. Evaluating Stenting in Challenging Coronary Indications/Patient Populations
    • 9.2.4. Targeting Patient Populations in the APAC Region

10. Current and Future Players

  • 10.1. Overview
  • 10.2. Trends in Corporate Strategy
  • 10.3. Company Profiles
    • 10.3.1. Abbott Vascular
    • 10.3.2. Boston Scientific Corporation
    • 10.3.3. Medtronic
    • 10.3.4. Alvimedica
    • 10.3.5. Amaranth Medical
    • 10.3.6. amg International
    • 10.3.7. Arterial Remodeling Technologies
    • 10.3.8. B. Braun
    • 10.3.9. Balton
    • 10.3.10. Biosensors International
    • 10.3.11. Biotronik
    • 10.3.12. Blue Medical
    • 10.3.13. Cardionovum
    • 10.3.14. C.R. Bard
    • 10.3.15. Elixir Medical Corporation
    • 10.3.16. eucatech AG
    • 10.3.17. Hexacath
    • 10.3.18. IRAMED
    • 10.3.19. JW Medical Systems
    • 10.3.20. Kyoto Medical Planning
    • 10.3.21. Lepu Medical Technology
    • 10.3.22. MicroPort Scientific Corporation
    • 10.3.23. Minvasys
    • 10.3.24. MIV Therapeutics
    • 10.3.25. Opto Circuits
    • 10.3.26. OrbusNeich Medical
    • 10.3.27. Relisys Medical Devices
    • 10.3.28. REVA Medical
    • 10.3.29. Sahajanand Medical Technologies
    • 10.3.30. STENTYS
    • 10.3.31. Terumo Corporation
    • 10.3.32. Translumina
    • 10.3.33. Vascular Concepts
    • 10.3.34. Other Companies

11. Market Outlook

  • 11.1. By Market Segment
    • 11.1.1. Overview
    • 11.1.2. Drug-Eluting Stent Market
    • 11.1.3. Bare Metal Stent Market
    • 11.1.4. Emerging Stent Technologies
  • 11.2. By Indication
  • 11.3. By Geography
    • 11.3.1. Overview
    • 11.3.2. United States
    • 11.3.3. 5EU
    • 11.3.4. Asia-Pacific
    • 11.3.5. Brazil

12. Appendix

  • 12.1. Bibliography
  • 12.2. Abbreviations
  • 12.3. Report Methodology
    • 12.3.1. Overview
    • 12.3.2. Coverage
    • 12.3.3. Secondary Research
  • 12.4. Physicians and Specialists Included in This Study
    • 12.4.1. Praveen Chandra, MD, DM, FESC, FSCAI, FAPSCI
    • 12.4.2. Bernado Cortese, MD, FESC
    • 12.4.3. Ricardo A. Costa, MD
    • 12.4.4. Thomas Cuisset, MD, PhD, FESC
    • 12.4.5. Nobuyuki Komiyama, MD, PhD, FACC, FJCC
    • 12.4.6. Roger J. Laham, MD
    • 12.4.7. Mark W. Mewissen, MD
    • 12.4.8. Gary S. Mintz, MD
    • 12.4.9. Tudor C. Poerner, MD
    • 12.4.10. David Ramsdale, MD, PhD
    • 12.4.11. Gregory A. Sgueglia, MD, PhD
    • 12.4.12. Madhukar Shahi, MD
    • 12.4.13. Takehiro Yamashita, MD, PhD, FACC
  • 12.5. Primary Research
    • 12.5.1. Primary Research - Key Opinion Leader Interviews
    • 12.5.2. Primary Research Interviews- Physician and Industry Participants
    • 12.5.3. Physican Survey
    • 12.5.4. Expert Panel Validation
  • 12.6. Forecasting Methodology
  • 12.7. About the Authors
    • 12.7.1. Analysts
    • 12.7.2. Global Head of Healthcare
  • 12.8. About MediPoint
  • 12.9. About GlobalData
  • 12.10. Disclaimer

List of Tables

  • Table 1: ACCF/AHA Treatment Guidelines to Improve the Symptoms of CAD*
  • Table 2: Types of CABG
  • Table 3: Complications of CABG
  • Table 4: Drugs Incorporated Into DES
  • Table 5: Types of Lesions Treated Using Atherectomy
  • Table 6: GPOs in the US and EU
  • Table 7: Medicare National Average of Inpatient Hospital Payment for CAD Therapeutic Procedures, 2013-2015
  • Table 8: Reimbursement Classification of Medical Devices in Japan
  • Table 9: Direct and Indirect Healthcare Costs of CAD
  • Table 10: Healthcare Expenditures ($bn, 2008$) for CAD in the US, 2011-2020
  • Table 11: Healthcare Expenditures ($bn) for CAD in the 5EU, 2006
  • Table 12: US Mean Hospital Costs* ($US) for Cardiac Revascularization Procedures, 2011-2020
  • Table 13: Coronary Stent Technology SWOT Analysis, 2014
  • Table 14: Global Coronary Stent Pipeline Products, 2014
  • Table 15: ART18Z SWOT Analysis, 2014
  • Table 16: DREAMS SWOT Analysis, 2014
  • Table 17: Fantom SWOT Analysis, 2014
  • Table 18: Fortitude SWOT Analysis, 2014
  • Table 19: Ideal BioStent SWOT Analysis, 2014
  • Table 20: Igaki-Tamai Stent SWOT Analysis, 2014
  • Table 21: ON-AVS SWOT Analysis, 2014
  • Table 22: Other Companies Developing BAS, 2014
  • Table 23: FOCUS np Eluting Stent SWOT Analysis, 2014
  • Table 24: STENTYS Sirolimus-Eluting Stent SWOT Analysis, 2014
  • Table 25: Svelte Drug-Eluting Stent SWOT Analysis, 2014
  • Table 26: Clinical Trials Evaluating the Latest and New Generation of DES, 2014
  • Table 27: Clinical Trials Evaluating Stenting in Challenging CAD Indications/Patient Populations, 2014
  • Table 28: Clinical Trials Evaluating Coronary Stenting in APAC Patient Populations, 2014
  • Table 29: Abbott Vascular Company Profile
  • Table 30: Abbott Vascular Coronary Stent Marketed Products
  • Table 31: Abbott Vascular Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 32: Abbott Vascular SWOT Analysis, 2014
  • Table 33: Boston Scientific Corporation Company Profile
  • Table 34: Boston Scientific Coronary Stent Marketed Products
  • Table 35: Boston Scientific Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 36: Boston Scientific Corporation SWOT Analysis, 2014
  • Table 37: Medtronic Company Profile
  • Table 38: Medtronic Coronary Stent Marketed Products
  • Table 39: Medtronic Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 40: Medtronic SWOT Analysis, 2014
  • Table 41: Alvimedica Company Profile
  • Table 42: Alvimedica Coronary Stent Marketed Products
  • Table 43: Alvimedica Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 44: Alvimedica SWOT Analysis, 2014
  • Table 45: Amaranth Medical Company Profile
  • Table 46: Amaranth Medical Coronary Stent Pipeline Product
  • Table 47: Amaranth Medical Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 48: Amaranth Medical SWOT Analysis, 2014
  • Table 49: amg International Company Profile
  • Table 50: amg International Coronary Stent Marketed Products
  • Table 51: amg International Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 52: amg International SWOT Analysis, 2014
  • Table 53: Arterial Remodeling Technologies Company Profile
  • Table 54: Arterial Remodeling Technologies Coronary Stent Pipeline Product
  • Table 55: Arterial Remodeling Technologies Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 56: Arterial Remodeling Technologies SWOT Analysis, 2014
  • Table 57: B. Braun Company Profile
  • Table 58: B. Braun Coronary Stent Marketed Products
  • Table 59: B. Braun Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 60: B. Braun SWOT Analysis, 2014
  • Table 61: Balton Company Profile
  • Table 62: Balton Coronary Stent Marketed Products
  • Table 63: BALTON Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 64: Balton SWOT Analysis, 2014
  • Table 65: Biosensors International Company Profile
  • Table 66: Biosensors International Coronary Stent Marketed Products
  • Table 67: Biosensors International Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 68: Biosensors International SWOT Analysis, 2014
  • Table 69: Biotronik Company Profile
  • Table 70: Biotronik Coronary Stent Marketed and Pipeline Products
  • Table 71: Biotronik Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 72: Biotronik SWOT Analysis, 2014
  • Table 73: Blue Medical Company Profile
  • Table 74: Blue Medical Coronary Stent Marketed Products
  • Table 75: Blue Medical Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 76: Blue Medical SWOT Analysis, 2014
  • Table 77: Cardionovum Company Profile
  • Table 78: Cardionovum Coronary Stent Marketed and Pipeline Products
  • Table 79: Cardionovum Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 80: Cardionovum SWOT Analysis, 2014
  • Table 81: C.R. Bard Company Profile
  • Table 82: ClearStream Technologies Coronary Stent Marketed Products
  • Table 83: C.R. Bard Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 84: C.R. Bard SWOT Analysis, 2014
  • Table 85: Elixir Medical Corporation Company Profile
  • Table 86: Elixir Medical Corporation Coronary Stent Marketed Products
  • Table 87: Elixir Medical Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 88: Elixir Medical Corporation SWOT Analysis, 2014
  • Table 89: eucatech Profile
  • Table 90: eucatech Coronary Stent Marketed Products
  • Table 91: eucatech Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 92: eucatech SWOT Analysis, 2014
  • Table 93: Hexacath Company Profile
  • Table 94: Hexacath Coronary Stent Marketed Products
  • Table 95: Hexacath Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 96: Hexacath SWOT Analysis, 2014
  • Table 97: IRAMED Company Profile
  • Table 98: IRAMED Coronary Stent Marketed Products
  • Table 99: IRAMED Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 100: IRAMED SWOT Analysis, 2014
  • Table 101: JW Medical Systems Company Profile
  • Table 102: JW Medical Systems Coronary Stent Marketed Product
  • Table 103: JW Medical Systems' Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 104: JW Medical Systems SWOT Analysis, 2014
  • Table 105: Kyoto Medical Planning Company Profile
  • Table 106: Kyoto Medical Planning Coronary Stent Pipeline Product
  • Table 107: Kyoto Medical Planning Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 108: Kyoto Medical Planning SWOT Analysis, 2014
  • Table 109: Lepu Medical Technology Company Profile
  • Table 110: Lepu Medical Technology Coronary Stent Marketed and Pipeline Products
  • Table 111: Lepu Medical Technology Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 112: Lepu Medical Technology SWOT Analysis, 2014
  • Table 113: MicroPort Scientific Corporation Company Profile
  • Table 114: MicroPort Scientific Corporation Coronary Stent Marketed Products
  • Table 115: MicroPort Scientific Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 116: MicroPort Scientific Corporation SWOT Analysis, 2014
  • Table 117: Minvasys Company Profile
  • Table 118: Minvasys Coronary Stent Marketed and Pipeline Products
  • Table 119: Minvasys Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 120: Minvasys SWOT Analysis, 2014
  • Table 121: MIV Therapeutics Company Profile
  • Table 122: MIV Therapeutics Coronary Stent Marketed Products
  • Table 123: MIV Therapeutics Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 124: MIV Therapeutics SWOT Analysis, 2014
  • Table 125: Opto Circuits Company Profile
  • Table 126: Opto Circuits Coronary Stent Marketed Products
  • Table 127: Opto Circuits Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 128: Opto Circuits SWOT Analysis, 2014
  • Table 129: OrbusNeich Medical Company Profile
  • Table 130: OrbusNeich Medical Coronary Stent Marketed and Pipeline Products
  • Table 131: OrbusNeich Medical Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 132: OrbusNeich Medical SWOT Analysis, 2014
  • Table 133: Relisys Medical Devices Company Profile
  • Table 134: Relisys Medical Devices Coronary Stent Marketed Products
  • Table 135: Relisys Medical Devices Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 136: Relisys Medical Devices SWOT Analysis, 2014
  • Table 137: REVA Medical Company Profile
  • Table 138: REVA Medical Coronary Stent Pipeline Product
  • Table 139: REVA Medical Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 140: REVA Medical SWOT Analysis, 2014
  • Table 141: Sahajanand Medical Technologies Company Profile
  • Table 142: Sahajanand Medical Technologies Coronary Stent Marketed and Pipeline Products
  • Table 143: Sahajanand Medical Technologies Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 144: Sahajanand Medical Technologies SWOT Analysis, 2014
  • Table 145: STENTYS Company Profile
  • Table 146: STENTYS Coronary Stent Marketed and Pipeline Products
  • Table 147: STENTYS Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 148: STENTYS SWOT Analysis, 2014
  • Table 149: Terumo Corporation Company Profile
  • Table 150: Terumo Corporation Coronary Stent Marketed and Pipeline Products
  • Table 151: Terumo Corporation Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 152: Terumo Corporation SWOT Analysis, 2014
  • Table 153: Translumina Company Profile
  • Table 154: Translumina Coronary Stent Marketed Products
  • Table 155: Translumina Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 156: Translumina SWOT Analysis, 2014
  • Table 157: Vascular Concepts Company Profile
  • Table 158: Vascular Concepts Coronary Stent Marketed Products
  • Table 159: Vascular Concepts Coronary Stent Product Portfolio SWOT Analysis, 2014
  • Table 160: Vascular Concepts SWOT Analysis, 2014
  • Table 161: Other Companies in the Coronary Stent Market, North America, 2014
  • Table 162: Other Companies in the Coronary Stent Market, EU, 2014
  • Table 163: Other Companies in the Coronary Stent Market, APAC, 2014
  • Table 164: Other Companies in the Coronary Stent Market, South Africa and South America, 2014
  • Table 165: Global Coronary Stent Sales ($m) Forecast, by Segment, 2011-2020
  • Table 166: Global DES Sales ($m) Forecast, 2011-2020
  • Table 167: Global BMS Sales ($m) Forecast, 2011-2020
  • Table 168: Coronary Stents Market Sales ($m) Forecast for the United States, 2011-2020
  • Table 169: EU Coronary Stent Sales ($m) Forecast, by Segment, 2011-2020
  • Table 170: Coronary Stents Market Sales ($m) Forecast for France, 2011-2020
  • Table 171: Coronary Stents Market Sales ($m) Forecast for Germany, 2011-2020
  • Table 172: Coronary Stents Market Sales ($m) Forecast for Italy, 2011-2020
  • Table 173: Coronary Stents Market Sales ($m) Forecast for Spain, 2011-2020
  • Table 174: Coronary Stents Market Sales ($m) Forecast for the UK, 2011-2020
  • Table 175: APAC Coronary Stent Sales ($m) Forecast, by Segment, 2011-2020
  • Table 176: Coronary Stents Market Sales ($m) Forecast for Japan, 2011-2020
  • Table 177: Coronary Stents Market Sales ($m) Forecast for China, 2011-2020
  • Table 178: Coronary Stents Market Sales ($m) Forecast for India, 2011-2020
  • Table 179: Coronary Stents Market Sales ($m) Forecast for Brazil, 2011-2020
  • Table 180: Primary Research Interviews Completed
  • Table 181: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Pathophysiology of CAD
  • Figure 2: CAD Treatment Modalities
  • Figure 3: Percentage of Patients with CAD Who Receive Each Therapy Option Only, Global, 2012 and 2019 (N=58)
  • Figure 4: Percentage of Patients with CAD Who Receive Each Type of PCI Only, Global, 2012 and 2019 (N=58)
  • Figure 5: Types of Stents Used to Treat CAD
  • Figure 6: Example of a BMS
  • Figure 7: Example of a DEB
  • Figure 8: Types of Atherectomy
  • Figure 9: Global Coronary Stenting Procedure Volume, 2011-2020
  • Figure 10: US Coronary Stenting Procedure Volume, 2011-2020
  • Figure 11: 5EU Coronary Stenting Procedure Volume, 2011-2020
  • Figure 12: APAC Coronary Stenting Procedure Volume, 2011-2020
  • Figure 13: Brazil Coronary Stenting Procedure Volume, 2011-2020
  • Figure 14: Healthcare Expenditures ($bn, 2008$) for CAD in the US, 2011-2020
  • Figure 15: US Mean Hospital Costs* ($US) for Cardiac Revascularization Procedures, 2011-2020
  • Figure 16: Percentage of CAD Patients with ISR, Global, 2012 and 2018 (N=58)
  • Figure 17: Percentage of CAD Patients Who Receive Stent-In-Stent Procedures, Global, 2012 and 2018 (N=58)
  • Figure 18: Interventional Cardiologists' Ranking of the Importance of Each Therapy Attribute in Adopting Stents for the Treatment of CAD, Global, 2013 (N=101)
  • Figure 19: Global Coronary Stents Market Value Share (%), 2013 and 2020
  • Figure 20: Global BMS Company Market Share (%), 2013
  • Figure 21: Global DES Company Market Share (%), 2013
  • Figure 22: US Market Share for BMS (%), 2013
  • Figure 23: US Market Share for DES (%), 2013
  • Figure 24: EU Market Share for BMS (%), 2013
  • Figure 25: EU Market Share for DES (%), 2013
  • Figure 26: APAC Market Share for BMS (%), 2013
  • Figure 27: APAC Market Share for DES (%), 2013
  • Figure 28: Brazil Market Share for BMS (%), 2013
  • Figure 29: Brazil Market Share for DES (%), 2013
  • Figure 30: Global Coronary Stent Pipeline Products by Stage of Development, 2014
  • Figure 31: Global Coronary Stents Market Revenue ($m), 2011-2020
  • Figure 32: Global DES Market Revenue ($m), 2011-2020
  • Figure 33: Global BMS Market Revenue ($m), 2011-2020
  • Figure 34: Percentage of Patients (%) Treated with Each Type of Coronary Stent Only, Global, 2013 and 2020 (N=101)
  • Figure 35: Percentage of Patients (%) Treated with Coronary Stents for Each Indication, Global, 2013 and 2020 (N=101)
  • Figure 36: Global Coronary Stents Market Revenue ($bn), 2013 and 2020
  • Figure 37: US Sales ($m) Forecast for Coronary Stents, 2011-2020
  • Figure 38: EU Sales ($m) Forecast for Coronary Stents, 2011-2020
  • Figure 39: French Sales ($m) Forecast for Coronary Stents, 2011-2020
  • Figure 40: German Sales ($m) Forecast for Coronary Stents, 2011-2020
  • Figure 41: Italian Sales ($m) Forecast for Coronary Stents, 2011-2020
  • Figure 42: Spanish Sales ($m) Forecast for Coronary Stents, 2011-2020
  • Figure 43: UK Sales ($m) Forecast for Coronary Stents, 2011-2020
  • Figure 44: APAC Sales ($m) Forecast for Coronary Stents, 2011-2020
  • Figure 45: Japanese Sales ($m) Forecast for Coronary Stents, 2011-2020
  • Figure 46: Chinese Sales ($m) Forecast for Coronary Stents, 2011-2020
  • Figure 47: Indian Sales ($m) Forecast for Coronary Stents, 2011-2020
  • Figure 48: Brazilian Sales ($m) Forecast for Coronary Stents, 2011-2020
Back to Top